U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07402876) titled 'A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma' on Jan. 29.
Brief Summary: A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Primary Vitreoretinal Lymphoma
Intervention:
DRUG: ICM ADX-2191 injection
Following the development of lymphomatous vitreous cells in at least one eye, subjects will follow ICM dosing with ADX-2191 intravitreal injectio...